Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer

Becton, Dickinson and Company371 enrolled

Overview

Multi-site, prospective performance study to determine equivalency between the investigational CLPD Limited Panel on the FACSLyric system versus the final clinical diagnosis.

Hematology laboratories rely on flow cytometry technology (in addition to classic hematological methods) to aid in screening, diagnosing, and monitoring patients with hematological disorders. High speed and broad applicability of flow cytometry allows for the diagnosis. Currently, there are no consensus panels being used; consequently, the leukemia \& lymphoma (L\&L) testing remains a single-vial antibody being used with various in-house laboratory developed tests (LDTs) being used to test patient specimens. Furthermore, the analysis of flow cytometer generated data is not standardized and requires a high level of expertise and training for interpretation of complex data. Therefore, optimized and standardized immunostaining protocols for the diagnosis, classification, and prognostic sub-classification of hematological malignancies are needed. This investigational reagent panel for chronic lymphoproliferative diseases (CLPD) is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations on the BD FACSLyric flow cytometer . These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, B-cell CLPD, T-cell CLPD, and NK-cell CLPD. Enrollment will occur at up to 8 investigational sites . Data will be acquired from Eligible remnant/leftover specimens on the BD FACSLyric flow cytometer and evaluated by site personnel and expert analysts . The final diagnosis and the affected cell population will be determined by site standard of care . Analysis of data will evaluate identification of normal vs abnormal cell population of the expert \& site analysts as compared to the final diagnosis.

Study Type

OBSERVATIONAL

Enrollment

371

Conditions

Chronic Lymphoproliferative Diseases (CLPD)

Interventions

IUO CLPD Limited PanelDIAGNOSTIC_TEST

This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having Chronic Lymphoproliferative Disease .

Eligibility

Sex: ALLMin age: 22 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Specimen collected/handled prior to enrollment in accordance with site policies and procedures. 2. Specimen with adequate volume (approximately 300 µL) to complete protocol tests. 3. Specimen is leftover PB, BM, or LN from routine flow cytometry laboratory testing for chronic lymphoproliferative disorders, other hematological disorders, non-hematological tumors (e.g., solid tumors), or other non-hematological disorders (non-malignant). 4. Specimen from newly diagnosed or relapsed subject. 5. Only one type of specimen, either PB, BM, or LN shall be enrolled per given subject. 6. Specimen is stored at room temperature, upon receipt by the site. 7. PB and BM specimens are collected in EDTA (K2 or K3) or heparin (sodium or lithium). 8. LN specimens collected in PBS, culture media (e.g., RPMI-1640), saline, or saline wrapped gauze at the discretion of the Investigator. 9. Age of specimen for PB and BM (time of collection to start of first pre-wash): ≤ 24 hours. (Note: No Age of specimen claim is being made for LN) 10. Specimens are from subjects irrespective of race, gender, and ethnicity. Exclusion Criteria: 1. Specimen is from healthy subject. 2. Specimen is from subject undergoing any treatment for any form of L\&L. 3. Specimen from subject \<22 years of age. 4. Specimen is from subject with minimal residual disease (MRD) as determined by the site. 5. Specimen is from subject suspected of acute leukemia (e.g., T-ALL, BCP-ALL, AML) or myeloid dysplastic syndrome (MDS). 6. Visibly clotted specimen. 7. Visibly hemolyzed specimen. 8. Frozen specimen. 9. Refrigerated specimen. 10. Fixed specimen.

Locations (6)

University of North Carolina

Chapel Hill, North Carolina, United States

Corepath Laboratories

San Antonio, Texas, United States

Champalimaud Foundation

Lisbon, Portugal

University of Salamanca

Salamanca, Spain

Outcomes

Primary Outcomes

Comparison between expert analysts' determination of normal and abnormal specimen and final diagnosis

Determine equivalence between the investigational OneFlow CLPD Limited Panel on FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for Normal (T-cell, B-cell, and NK-cell) or Abnormal (T-cell or B-cell or NK-cell) phenotype using leftover, hematologically abnormal specimens . Sensitivity and specificity are calculated

Time frame: Age of specimen for PB and BM (time of collection to start of first pre-wash): ≤ 24 hours.

Secondary Outcomes

Comparison between expert analysts' determination of normal and abnormal Peripheral Blood (PB) specimen and final diagnosis

Determine equivalence between the investigational OneFlow CLPD Limited Panel on FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for Normal or Abnormal phenotype using leftover, hematologically abnormal peripheral blood (PB) specimens. Sensitivity and specificity are calculated .

Time frame: Age of specimen for PB (time of collection to start of first pre-wash): ≤ 24 hours.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.